Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ambroxol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.97 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.41 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.41 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.41 |
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | GBA1 | P04062 | 1/20 | 0.97 |
| ▸ | CNR1 | P21554 | 1/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.97 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ambroxol SCHEMBL6601413 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL18702 | 0.99 | CYP2D6 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL7855003 | 0.99 | CYP2D6 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL423712 | 0.99 | CYP2D6 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL29380194 | 0.99 | CYP2D6 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL28472066 | 0.99 | CYP2D6 (1.00) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL1648757 | 0.96 | CYP2D6 (0.94) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| Ambroxol SCHEMBL11533052 | 0.92 | CYP2D6 (0.87) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| SCHEMBL24446418 | 0.90 | CYP2D6 (0.84) | CYP3A4ALOX15TSHRTDP1CYP2D6 | |
| SCHEMBL22927201 | 0.90 | CYP2D6 (0.84) | CYP3A4ALOX15TSHRTDP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4457 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070909-A | Ambroxol anhydrous swallow granule and preparation method thereof | 华益泰康药业股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| EP-4724103-A1 | AMBROXOL LIQUID FORMULATION | R.P. Scherer Technologies, LLC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4705274-A1 | MODIFIED FORMS OF AMBROXOL FOR THERAPEUTIC USE | Zywie LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4681706-A1 | LIQUID PREPARATION ALLOWING FOR NEBULIZATION INHALATION, CARTRIDGE, AND AEROSOL GENERATION SYSTEM | Shenzhen First Union Technology Co., Ltd. (CN) | 2026-01-21 | — | — | EP | claimed |
| EP-4603084-A1 | AMBROXOL ORAL DISSOLVING FILM COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Aurora Biotechnology Co., Ltd. (CN) | 2025-08-20 | — | — | EP | claimed |
| US-20250235413-A1 | MODIFIED FORMS OF AMBROXOL FOR THERAPEUTIC USE | ZYWIE, LLC (US) | 2025-07-24 | — | — | US | claimed |
| US-12364673-B2 | Methods and compositions for treating lysosomal storage disorders: ambroxol as treatment agent for Mucopolysaccharidoses III (Sanfilippo syndrome) | Lysosomal and Rare Disorders Research and Treatment Center, Inc. (US) | 2025-07-22 | — | — | US | claimed |
| CN-119936272-B | Method for detecting N-nitrosoambroxol in medicine by LC-MS/MS | 亚宝药业四川制药有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-120131689-A | Compound roxithromycin composition and preparation method thereof | 江苏亚邦爱普森药业有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-120114422-A | Atomized inhalation solution for treating bronchial asthma and preparation method and application thereof | 中南大学湘雅二医院 | 2025-06-10 | — | — | CN | claimed |
| US-6251429-B1 | EXPECTORANTS | THERAPICON SLR (IT) | 2001-06-26 | — | — | US | claimed |
| CN-1276246-A | Process for preparing medicines with no or low loxic by-effect on gastrointestinal system | WANG XIAO (CN) | 2000-12-13 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5762951-A | ANALGESICS, ANTACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-06-09 | — | — | US | claimed |
| EP-0546846-B1 | Programmed-release pharmaceutical compositions | THERAPICON SRL (IT) | 1997-01-22 | — | — | EP | claimed |
| EP-0491910-B1 | PHARMACEUTICAL COMPOSITION FOR RAPID SUSPENSION IN WATER | EURAND INT (IT) | 1994-11-09 | — | — | EP | claimed |
| EP-0546846-A1 | Programmed-release pharmaceutical compositions | THERAPICON SRL (IT) | 1993-06-16 | — | — | EP | claimed |
| EP-0491910-A1 | PHARMACEUTICAL COMPOSITION FOR RAPID SUSPENSION IN WATER. | EURAND INT (IT) | 1992-07-01 | — | — | EP | claimed |
| WO-1992000731-A1 | PHARMACEUTICAL COMPOSITION FOR RAPID SUSPENSION IN WATER | EURAND INTERNATIONAL SPA (IT) | 1992-01-23 | — | — | WO | claimed |
| EP-0125634-B1 | USE OF A SECRETOLYTICALLY ACTIVE SUBSTANCE FOR THE MANUFACTURE OF A REMEDY AGAINST SNORING AND FOR COMBATING SNORE PHENOMENON | Reichert, Dietrich, Dr. med. (ES) | 1990-09-26 | — | — | EP | claimed |